Skip to content

Nasal high flow (NHF) with expiratory flow reduction effects on ventilation, adherence and gas exchange in the treatment of hypercapnic COPD.

Nasal high flow (NHF) with expiratory flow reduction effects on ventilation, adherence and gas exchange in the treatment of hypercapnic COPD. - NHFRelief2024

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035771
Enrollment
30
Registered
2025-01-02
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44.0

Interventions

one night NHF, questionnaires CAT, MDP) Group 2: 1st NHFrelief with 50 L/min and flow reduction
2nd NHFconst with 30 L/min (respiratory physiological measurements for 60 min during the day
Group 1: 1st NHFconst with 30 L/min
2nd NHFrelief with 50 L/min and flow reduction (respiratory physiological measurements for 60 min during the day
one night NHF, questionnaires CAT, MDP)

Sponsors

Klinikum Dortmund gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: - Male and female patients - Age 18 to 90 years - COPD patients GOLD (2, 3 and 4) who are hospitalized due to an exacerbation - Written consent after detailed verbal and written information is a prerequisite for participation

Exclusion criteria

Exclusion criteria: - Acute respiratory insufficiency with clinical instability or respiratory acidosis defined by pH<7.35 - Severe acute physical illness that does not allow the subject to participate in a clinical trial - Not able to give consent - Linguistic, cognitive or other barriers that make participation in the study impossible

Design outcomes

Primary

MeasureTime frame
Comparison of the average respiratory minute volume as a parameter for the differences in work of breathing resulting from the use of NHFrelief (50L/min) compared to NHFconst (30L/min).

Secondary

MeasureTime frame
Comparison of the transcutaneously measured PCO2 during the therapy nights Comparison of CAT questionnaire score after the therapy nights Comparison of MDP dyspnea questionnaire score after the therapy nights

Countries

Germany

Contacts

Public ContactUlrike Domanski

Klinikum Dortmund gGmbH

Ulrike.Domanski@klinikumdo.de+49(0)231 953 36286

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026